We have previously shown, in the estrogen-unresponsive C3H mouse mammary tumor that the affinity of the estrogen receptor (ER) for calf thymus DNA in vitro is four-times higher than that of uterine ER [Baskevitch, P. P., Vignon, F., Bousquet, C. and Rochefort, H. (1983) Cancer Res. 43,22901. By mixing cytosols from this tumor and uterus, we describe a tumor factor capable of increasing ER affinity for DNA, as assayed by DNA-cellulose chromatography and saturation studies. The activity of this factor was inhibited by a-chymotrypsin-inhibitors such as N-tosylphenylalanylchloromethane and chymostatin. Using the fluorogenic substrate glutarylglycylglycylphenylalanyl-N-naphthylamide, we assayed such a protease in the C3H mammary tumor cytosol. This protease and the factor altering ER-DNA binding were eluted together from chromatography on DEAE-cellulose, AcA 44, and carboline-agarose and were sensitive to the same inhibitors. The partially purified factor decreases the molecular mass of the estrogen receptor as seen by denaturing electrophoresis after covalent labelling of the ER with [3H]tamoxifen aziridine. We suggest that the increase of ER affinity for DNA and the decrease of ER molecular size are due to the same protease with an a-chymotrypsin-like specificity.Systems resistant to steroid hormones are useful in analyzing the sequence of hormone action, particularly the nuclear and DNA binding of the receptor-hormone complex, and in determining their biological significance [I]. In mammary tumors, estrogen resistance is mostly associated with the lack of assayable estrogen receptor sites [2]. However, in humans, 50% of breast cancers which possess estrogen receptor (ER-positive) do not respond to endocrine therapy. One possibility is that the ER are present, and are capable of binding the hormone, but are unable to transduce the message efficiently to chromatin. In this respect, hormone-resistant and ER-positive experimental mammary tumors are particularly interesting.We have investigated the ER system in the C3H mouse mammary carcinoma. This tumor is estrogen-unresponsive since in vivo estradiol is unable to increase the concentration of the progesterone receptor sites, and does not sustain tumor growth [3, 41. In this tumor, the ER is present at moderate concentrations (20 -40 fmol/mg cytosol protein) and, after estrogen binding, is translocated into the nucleus in vivo [3]. Therefore the estrogen-unresponsiveness of the tumor is not due to the absence of nuclear ER. It may therefore be the consequence of a post-receptor defect [5]. We have recently shown that the ER from C3H tumor has a fourfold higher affinity in vitro for non-specific DNA as compared to the ER